

Q3 21 Earnings Call

10 November 2021

Disclaimer

Use of Non-GAAP Financial Measures

This Presentation includes non-GAAP financial measures. Cellebrite believes that these non-GAAP measures are useful to investors for two principal reasons. First, Cellebrite believes these measures may assist investors in comparing performance over various reporting periods on a consistent basis by removing from operating results the impact of items that do not reflect core operating performance. Second, these measures are used by Cellebrite's management to assess its performance. Cellebrite believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends. These non-GAAP measures should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. Other companies may calculate these non-GAAP financial measures differently, and therefore such financial measures may not be directly comparable to similarly titled measures of other companies. A reconciliation of each of these non-GAAP financial measures to their most comparable GAAP measure is set forth in a table included at the end of this Presentation.

Forward Looking Statements

This Presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "may", "should", "plan", "intend", "expect", "believe", "anticipate", "estimate", "predict", "potential", "seem", "seek", "continue", "future", "will", "outlook", or other similar expressions, words or phrases are intended to identify forward-looking statements. These statements include statements regarding the industry in which Cellebrite operates, future events and other statements that are not historical facts. These statements are made on the basis of current knowledge and current expectations of Cellebrite management and, by their nature, involve numerous assumptions and uncertainties and are not predictions of actual performance. Nothing set forth herein should be regarded as a representation, warranty, or prediction that Cellebrite will achieve or are likely to achieve any particular future result.

Various factors could cause actual future results, performance or events to differ materially from those described herein. This Presentation does not purport to be all-inclusive or to contain all the information that a prospective investor may desire in making an evaluation. The matters discussed in this presentation also involve risks and uncertainties summarized under the heading "Risk Factors" in Cellebrite's Registration Statement on Form F-1 filed with the Securities and Exchange Commission on September 27, 2021.

Some of the factors that may impact future results and performance may include, without limitation:

- The impact of pending and future litigation and governmental investigations and inquiries;
- Changes in U.S. federal, U.S. state, and non-U.S. laws and regulations, their interpretation, their enforcement, or the regulatory climate applicable to our business, and their impact on our ability to operate our business;
- Errors, failures, defects or bugs in our products, which could expose us to financial and legal harm and adversely affect our operating results and growth prospects; and
- Some of our solutions may be used by customers in a way that is, or that is perceived to be, incompatible with human rights. Any such perception could adversely affect our reputation, revenue and results of operations
- Any non-compliance with the Israeli encryption laws and governmental trade controls, including export and regulations could negatively impact our operating results.

Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



Business Overview



Q3 21 customer successes



Premium: New Licenses


- ✤ 2 U.S. federal agencies
- ✤ U.S. state police
- + European ministry of interior affairs
- ✦ Near East city police
- + And more...

Premium Enterprise

- + U.K. county police
- ✤ 2 U.S. county sheriff offices
- Customs agency
- + And more...


Q3 21 customer successes: Example 1

National correction facilities network




Q3 21 customer successes: Example 2

European country national police



6

Massive digital intelligence market – \$13B+ TAM in 2023



TAM by Domain

Sources: Cellebrite proprietary research 2020.

¹ Corporate investigations.; ² 250 Tier 1 agencies, 850 Tier 2 agencies and 5,300 Tier 3 agencies.; ³ Assumes Tier 3 agencies do not purchase analytics tools.; ⁴ Refers to software solutions only, ComplexDiscovery.; ⁵ Blended spend per agency (the higher the agency Tier the larger the spend per agency).; ⁶ Homeland Security Research 2021



Cellebrite delivers a comprehensive DI software platform



COLLECT & REVIEW

Fast and Automated approach to capturing data from digital sources


ANALYZE

Processing the data fast with advanced analytics and Al

MANAGE



Breaking down silos and enabling collaboration



DATA TYPES

Empowering Chiefs of Investigations & Intelligence with end-to-end investigative platform



Cellebrite Guardian

کے	\frown	5
(J

First SaaS solution, more efficient and cost effective

_	
)==

Accelerates review with inbrowser reports viewing

٦	_
٦	—
٦	_

Repository for all digital *and* physical evidence records



Enables real-time collaboration

Partiner Consistence Parding Analysis Parding Analysis Parding Parking Parding Parking Parding Parking Parding Parking Parding Parking <	Durkbard Unassigned Pending Analysis Pending Review Approval My Custody My Custody Wy Active Section Unclaimed Section Active Section Pending Review All My All Section All Active All Pending Review All Pending Review All My My Active Section Unclaimed Section Active Section Pending Review All My All Section All Active All Pending Review All My All Section All Active All Pending Review All My All Section All Pending Review All My All Section All Pending Review All My All Section All Active All Pending Review All My All Section All Pending Review All My All Section All Pending Review All My All Section All Pending Review All My	GUARDIAN										x 🖉	U Dem	io Analy
Review/Approval Wy Active Section Undaimed Section Active Section Pending Review All M All Section All Active All Pending Review All Pending Review <t< th=""><th>Ender Control Contro Control Control</th><th>(?) Dashboard</th><th></th><th>passigned</th><th>•</th><th>Ponding Anal</th><th></th><th>$\overline{\mathbf{X}}$</th><th>Donding</th><th>0</th><th></th><th>Mu Custor</th><th></th><th>2</th></t<>	Ender Control Contro Control Control	(?) Dashboard		passigned	•	Ponding Anal		$\overline{\mathbf{X}}$	Donding	0		Mu Custor		2
My Active Section Unclaimed Section Active Section Pending Review All My All Section All Active All Pending Review All Pend	My Active Section Unclaimed Section Active Section Pending Review All My All Section All Active All Pending Review All International Internatio International Internatio International Inte			nassigneu		Pending Ana	iysis					wy custor	у	
Receive C Image: Control Start Ima	Receive C Description Description <thdescription< th=""> Description <thdescripti< th=""><th></th><th>My A</th><th>Active Sect</th><th>tion Unclaimed</th><th>Section Active Se</th><th>ction Pendin</th><th>g Review All My</th><th>All Sect</th><th>ion All</th><th>Active All Pe</th><th>nding Review</th><th>All I</th><th>tems</th></thdescripti<></thdescription<>		My A	Active Sect	tion Unclaimed	Section Active Se	ction Pendin	g Review All My	All Sect	ion All	Active All Pe	nding Review	All I	tems
C 28 B/52020-00010 PD E/dence Police Department PDE202000900 Burglary Digital Forensics Pending Analysis Demo Nalysis 2021-03-11 13.37.21 2021-03-11 13.37.21 111 11 Riports C B/52020-00010 PD E/dence Police Department PDE2020500700 Forgery Drug identification Rendrag Dama 2021-03-11 13.37.21 13.	C 28 Bj52020-0000 PD Evidence Pallee Department PDE20200500700 Burglary Digital Forensics Printing Analysis Demo 13:37:21 20:21-03:11 20:21-03:11 11:1 1 Image: C 28 Bj52020-00000 PD Evidence Pallee PDE20205500700 Forgery Drug Identification Panding Damo 20:21-03:11 20:21-03:11 31:37:21							Press Enter to	o Search					0 2
Reports Column Section Spectrometric PDE202000000 Department PDE202000000 Burgary Digital Forensics Analysis	Image: space of		ID 🔻 Ca	ise Number 🔅		Agency Reference	Case Type	Assignment Type					0 Age 0	Item
Reports C 25 Space-scale Pole-scale Pole-scale <t< td=""><td>Reports C ZD Biss0000000 Department Program Drog benefinication Analysis Analysis</td><td></td><td>28 B</td><td>3JS2020-00010</td><td></td><td>PDE2020000900</td><td>Burglary</td><td>Digital Forensics</td><td></td><td></td><td></td><td></td><td>111</td><td>1</td></t<>	Reports C ZD Biss0000000 Department Program Drog benefinication Analysis		28 B	3JS2020-00010		PDE2020000900	Burglary	Digital Forensics					111	1
Image:	Image: Constraint in the state of		25 B	3JS2020-00002		PDE20200500700	Forgery	Drug Identification					335	1
9 BjS2020-00004 Department 2020-0529 Theft Digital Forensics Preading Demos 2020-0549 330 1 ** 2 BjS2020-00004 PD Evidence Police PDE2020050700 Forgery Digital Forensics Pending 2020-05-9 2020-05-28 398 1 ** 2 BjS2020-00002 PD Evidence Police PDE20200500700 Forgery Digital Forensics Pending 2020-05-28 398 1	9 BJS2020-00004 Department 2020-0529 Theft Digital Forensics Analyst 2020-0529 Total Advise 2020-0529		13 B	BJS2020-00011		PDE20200600899	Burglary	Digital Forensics					387	1
4dmin C 2 BjS2020-00002 FDC20200500700 Forgery Digital Forensics Analyst 11:29:39 T7:50:39 328	C 2 Bj32020-00002 PDE20200500700 Forgery Digital Forensics Analysit Analysit 11:29:39 ************************************	Audit	9 B	3JS2020-00004		2020-0529	Theft	Digital Forensics				2020-06-05 16:39:45	390	1
	Showing 1 to 5 of 5 rows		2 B	3JS2020-00002		PDE20200500700	Forgery	Digital Forensics					398	1
			Jiowing Fo	5000										



Remote Mobile Collection

=







Digital Clues acquisition

Cellebrite + DIGITAL CLUES



Yossi Carmil Cellebrite CEO (left) Yossi Ofek, chairman and CEO at Digital Clues

KICKSTART INVESTIGATIONS

OSINT Solutions to Capitalize on Crucial Early Hours of an Investigation



Investment highlights



Cellebrite is the clear market leader within digital intelligence



Massive \$13B+ market opportunity for digital intelligence ("DI") solutions with major secular tailwinds supporting continued growth



Unique mission critical end-to-end digital intelligence platform that serves the world's leading government agencies and enterprises at each stage of the investigative lifecycle



Rapidly growing Enterprise opportunity with segment revenue projected to double by 2023



Fragmented landscape of point solutions with numerous actionable targets and significant resources to support execution of highly strategic M&A thesis



World class, mission driven management team with deep industry expertise



Compelling financial profile with 42% ARR growth and 139% ARR net retention in LTM September 2021



Cellebrite


Financial Overview

Financial highlights

 $\langle \sim \rangle$ Best-in-class ARR & NRR 42% ARR Growth Q3 '21 139% Net Retention LTM Sep-21

Note: non-GAAP metrics defined in the appendix.


Top-line Growth & Scale \$66M Total Revenue Q3 '21 24% Revenue Growth Q3 '21




14




Revenue growth driven by subscription





15


ARR growth driven by expansion





Profitability expansion


Gross profit (\$M) and margin




Looking Ahead

- 🔸 Travel
- Field marketing events
- Hiring ~60 employees
- ✤ R&D investment
- Public company costs

Operating expenses (Non-GAAP, \$M) and % of sales



Adj. EBITDA (\$M) and margin





Net income, EPS and share count

(\$K, except EPS)	Sep 20	Sep 21
GAAP Net Income	8,121	8,139
One-time tax expense	-	7,067
Issuance expenses	-	11,834
Dividend participation compensation	-	966
Share based compensation expenses	1,825	1,417
Amortization of intangible assets	386	541
Acquisition related costs	1,391	1,802
Income tax income	(207)	(1,210)
Financial income	-	(17,252)
Non-GAAP Net Income	11,516	13,303
WASO, diluted	157,968,025	163,348,212
Non-GAAP EPS	0.07	0.08

(in '000, rounded)	New Structure
Total Company Shares Outstanding	180,000
Cellebrite Options	18,500
WASO, diluted	198,500
Restricted Sponsor Shares	7,500
Cellebrite Price Adjustment Shares	15,000
Private Warrants	9,667
Public Warrants (CLBTW)	20,000

Financial forecas	St 2021E old		2021E new
ARR	\$197M	•	
ARR Growth	44%		~34%
Revenue	\$236M		\$241.5-243.5M
Revenue Growth	21%		24%*
Adjusted EBITDA	\$36M		\$45.0-46.5M
Adjusted EBITDA Margin	15%	-	19%*

* At guidance mid point





Appendix



Financial summary – Q3

(\$K)	Sep 20A	Sep 21A
ARR	120,874	171,343
YOY Growth - %	46%	42%
Subscriptions	35,004	51,251
Perpetual License & Others	11,838	6,657
Professional Services	6,399	7,979
Total Revenue	53,241	65,887
YOY Growth - %	25%	24%
Gross Profit	43,740	53,933
Gross Profit - %	82.2%	81.9%
Adjusted EBITDA	13,888	15,025
Non-GAAP EBITDA - %	26.1%	22.8%

Adjusted EBITDA reconciliation – Q3

(\$K)	Sep 20A	Sep 21A
Net Income	8,121	8,139
Financial income, net	(417)	(17,811)
Tax expenses	1,279	6,581
Issuance expenses	-	11,834
Dividend participation compensation	-	966
Share based compensation	1,825	1,417
Amortization of intangible assets	386	541
Acquisition related costs	1,391	1,802
Non-GAAP EBIT	12,585	13,469
Non-GAAP EBIT - %	23.6%	20.4%
Depreciation & Amortization	1,303	1,556
Adjusted EBITDA	13,888	15,025
Adj EBITDA - %	26.1%	22.8%

Definitions

- 1. Annual Recurring Revenue: Annual recurring revenue ("ARR") is defined as the annualized value of active term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Subscription license contracts and maintenance contracts for perpetual licenses are annualized by multiplying the revenue of the last month of the period by 12.
- 2. Subscription Revenue: Is defined as revenue from recurring, term-based license contracts and ongoing services related to core offerings. Subscription revenue is recognized ratably over the subscription term with a portion of revenue, related to the term-based license, recognized upfront.
- 3. Net Retention: Dollar-based net retention rate is calculated by dividing customer recurring revenue by base revenue. We define base revenue as recurring revenue we recognized from all customers with a valid license at the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define our customer revenue as the recurring revenue we recognized during the four quarters ended on the date of measurement from the same customer base included in our measure of base revenue, including recurring revenue resulting from additional sales to those customers.
- 4. Gross Retention: Gross revenue retention is calculated by dividing customer revenue excluding upsells by base revenue. We define base revenue as revenue we recognize from all customers in the last quarter of the previous year period, during the four quarters ended one year prior to the date of measurement. We define customer revenue excluding upsells as the revenue we recognize during the four quarters ended on the date of measurement from the same customer base included in our measure of base revenue, excluding upsells / cross-sells. The measure captures the weighted average dollar loss versus 100% from the customer base.

